All In MedTech

FDA Clearance Tracker · P790019-S011

ABBOTT AXSYM HAVAB-M 2.0

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 2, 2004 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P790019-S011
Device name
ABBOTT AXSYM HAVAB-M 2.0
Applicant location
Abbott Park North, IL
Received
Jun 9, 2000
Decided
Feb 2, 2004
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P790019

Device type

Device class
Class II
Regulation
21 CFR 866.3310

Every decision under product code LOL

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE ABBOTT AXSYM HAVAB-M 2.0. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME AXSYM HAVAB-M 2.0 AND IS INDICATED FOR THE QUALITATIVE DETECTION IF IGM ANTIBODY TO HEPATITIS A VIRUS (IGM ANTI-HAV) IN HUMAN SERUM OR PLASMA. A TEST FOR IGM ANTI-HAV IS INDICATED AS AN AID IN THE DIAGNOSIS OF ACUTE OR RECENT HEPATITIS A VIRAL INFECTION.

Source documents

Other decisions for Abbott Laboratories

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.